Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Penicillin-binding protein 1

5

Penicillin-binding protein 1A

5

Penicillin-binding protein 1B

5

Penicillin-binding protein 2

5

Penicillin-binding protein 3

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1985

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cystic fibrosis

5

Lower respiratory tract infections

5

Skin and skin structure infections

5

Urinary tract infections

5

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

5

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Glaxo

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

EPA CompTox

5

FDA UNII

5

PUBCHEM

5

EVMPD

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER BETA-LACTAM ANTIBACTERIALS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Third-generation cephalosporins

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Ceftazidime anhydrous

DZR1ENT301

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

Ceftazidime anhydrous, (E)-

UU1494IX6R

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

Ceftazidime dihydrochloride

8ORW199D1G

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

CEFTAZIDIME SODIUM

CMC30V039K

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

Ceftazidime

9M416Z9QNR

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Penicillin-binding protein 1

Penicillin-binding protein 4

Penicillin-binding protein 1A

Penicillin-binding protein 2

Penicillin-binding protein 1B

Penicillin-binding protein 3

Conditions:

Urinary tract infections

Skin and skin structure infections

Lower respiratory tract infections

Cystic fibrosis

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...

m, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1